RxDoctor Payments Data

Monica Egozcue Dionisi, MD

Pulmonary Disease · Mayaguez, PRNPI 1215185343

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $840, 2.5 times the $334 reported in 2019.

$3,382in general payments, 2019–2025

Across 120 payments — averaging $28.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$578
  • AstraZeneca$423
  • Boehringer Ingelheim$423
  • Johnson & Johnson$289
  • United Therapeutics Corporation$272
  • Viatris Specialty LLC$261
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$3,382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK21$578
AstraZeneca14$423
Boehringer Ingelheim15$423
Johnson & Johnson9$289
United Therapeutics Corporation8$272
Viatris Specialty LLC10$261
E.r. Squibb & Sons, L.L.C.4$182
Takeda Pharmaceuticals U.S.A., Inc.7$179
Mylan Specialty L.p.8$177
Sanofi8$174
PBG Puerto Rico LLC4$92
Merck3$87
ANI Pharmaceuticals, Inc.3$86
Olympus Latin America, Inc.2$81
Amgen3$66
Mylan LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,382 in reported general payments places this provider in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,388
Medicare patients
56
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate106$1,286,780
AdempasRiociguat59$812,276
Trelegy ElliptaFluticasone/Umeclidin/Vilanter429$284,781
Breo ElliptaFluticasone/Vilanterol167$67,066
Stiolto RespimatTiotropium Br/Olodaterol Hcl73$35,897
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr69$33,084
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate113$32,183
Fluticasone Propionate HfaFluticasone Propionate76$20,521
Arnuity ElliptaFluticasone Furoate77$16,842
Pirfenidone12$11,957
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,816
Spiriva RespimatTiotropium Bromide18$9,700
Incruse ElliptaUmeclidinium Bromide15$5,380
SymbicortBudesonide/Formoterol Fumarate23$5,249
Qvar RedihalerBeclomethasone Dipropionate14$4,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$423$1,332,378197 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$578$407,153757 claims
AstraZenecaBreztri Aerosphere, Symbicort$423$17,06541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →